AVTX
AVTX
US05338F3064
Avalo Therapeutics, Inc.
Loading chart...

Financials

Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
Breakdown 2025 2024 Change %
Total Revenue 59.000 441.000
86.6%
Cost of Revenue -- -366.000
--
Gross Profit 59.000 807.000
92.7%
72.984.000 41.678.000
75.1%
Operating Income -72.925.000 -40.871.000
78.4%
Pretax Income -78.094.000 -35.015.000
123.0%
Net Income Common Stockholders -78.259.000 -35.129.000
122.8%
-- --
--
-- --
--
ende